0

Hoag is First in Nation to Test Innovative Antibody Brain Cancer Drug

NEWPORT BEACH, Calif., May 19, 2020 /PRNewswire/ — Hoag Family Cancer Institute and Pickup Family Neurosciences Institute at Hoag, in collaboration with Nascent Biotech, Inc announced today [...]

0

Nascent Biotech and Manhattan BioSolutions Enter into Collaboration to Advance Vaccine Discovery and Development for COVID-19

San Diego, CA, May 12, 2020—Nascent Biotech, Inc (OTCQB: NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers and viral infections, [...]

0

Nascent Biotech: This Cancer Research Microcap Has A Drug in Testing with Indications for Use Against COVID-19

As the world of pharma and biotech companies works towards finding a solution for COVID-19, we see a number of different research-oriented companies emerging. Many of these companies specialize [...]

0

Nascent Biotech’s Independent Consultants have begun Research on Pritumumab as a Potential Therapeutic Agent against (Coronavirus) Covid-19

April 7, 2020 San Diego, CA USA. – Nascent Biotech, Inc. (OTCQB: NBIO), today announced that two independent consultants retained by the Company have begun preliminary research on a [...]

0

Nascent Biotech Investigation Drug Product, Pritumumab, to be Studied as a Potential Therapeutic agent against (Coronavirus) Covid-19

March 3, 2020 San Diego, CA USA. – Nascent Biotech, Inc. (OTCQB: NBIO), today announced its intention to begin research on a possible treatment for patients infected with the Coronavirus. [...]

0

HUMAN ANTIBODIES & HYBRIDOMAS 2020

Nascent Biotech founder Dr. Mark C. Glassy will once again be organizing and speaking at the Human Antibodies & Hybridomas conference, held 11-13 November 2020, The Richard Doll Building, [...]

0

Recent Publications from Nascent Biotech Founder Dr. Mark C. Glassy

Click each link to download individual publications in PDF format. Brain‐derived neurotrophic factor downregulation in gastric cancer Antibody drug conjugates: Progress, pitfalls, and promises [...]

0

Human Antibodies: Antibody drug conjugates: Progress, pitfalls, and promises

Nascent Biotech founder Dr. Mark C. Glassy has co-authored a new paper appearing in Human Antibodies entitled, “Antibody drug conjugates: Progress, pitfalls, and promises.” Please [...]

0

Nascent Biotech Receives Clearance from FDA to Begin Phase I Human Trials in Brain Cancer

Vero Beach, FL December 10, 2018 – Nascent Biotech, Inc. (OTC: NBIO) Received US Food and Drug Administration (FDA) Clearance to begin Phase 1 Clinical Trials effective December 7th, 2018. [...]

0

Prionogenicity of vimentin surmised from the sequelog of anti-idiotypic antibodies toward the paratope of malignant associated autologous anti-vimentin antibody, CLN-IgG (Pritumumab)

The British Journal of Cancer Research has just released a new paper co-authored by Nascent Biotech founder Dr. Mark C. Glassy entitled, “Prionogenicity of vimentin surmised from the [...]

page 1 of 3